You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Adjusted annual direct costs ($) by type of comorbidity

From: Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database

Comorbidity No. of patients with comorbidity Adjusted costs for patients with comorbidity No. of patients without comorbidity Adjusted costs for patients without comorbidity Incremental adjusted costs Lower 95% CL Upper 95% CL
Psoriatic Arthritis 5557 25,035.9 50,849 13,376.2 9914.3 9215.8 10,612.7
Cardiovascular disease 9992 22,287.1 46,414 12,853.8 8275.1 5900.6 7630.0
Depression 4388 20,270.7 52,018 14,040.2 6765.3 1188.2 2081.8
Anxiety 3148 17,569.3 53,258 14,344.9 4181.2 6682.3 10,090.7
Diabetes 8031 22,052.1 48,375 13,275.2 6911.4 6271.3 7551.5
Hyperlipidemia 18,911 16,502.7 37,495 13,527.3 1635.0 6254.9 7024.3
Hypertension 19,365 18,465.9 37,041 12,464.5 4522.3 5754.1 8255.9
Obesity 2755 20,827.1 53,651 14,201.2 6564.5 5419 7710.1
Cerebrovascular disease 2122 23,410.0 54,284 14,177.5 7005.0 2950.6 5411.9
Peripheral vascular disease 2032 24,871.7 54,374 14,138.2 8386.5 7461.2 9089
Any of the comorbiditiesa 35,644 17,425.8 20,762 9544.5 6639.6 4033.5 5011.2
  1. Note: The adjusted costs were predicted based on the model results using the recycled prediction method [38] for patients with and without comorbidities using the study sample. The incremental adjusted costs are differences in the adjusted costs between patients with and without comorbidities. The 95% CLs were calculated using bootstrapping method for both direct and indirect costs
  2. aAny of the above comorbidities means if patients have any of the either comorbidities mentioned above